跳至主要内容
临床试验/NCT01948765
NCT01948765已完成2 期

Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery:a Randomised Controlled Trial

Universitaire Ziekenhuizen KU Leuven1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2013年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
1
主要终点
intraoperative haemodynamic stability

研究概览

简要总结

The investigators hypothesize that the application of 30% xenon as an adjuvant to general anesthesia with a target-controlled infusion of propofol is superior to general anesthesia with propofol alone with respect to hemodynamic stability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with coronary artery disease scheduled for elective OPCAB-surgery
  • patients willing and able to complete the requirements of this study
  • Ejection fraction >30%

排除标准

  • Lack of informed consent
  • age < 18 years
  • COPD GOLD >II
  • Renal dysfunction defined as serum-creatinine >1.5mg/dl
  • acute coronary syndrome during the last 24 hours; haemodynamic instability, requirement of inotropic support
  • single vessel grafting
  • disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease, schizophrenia, depression, low preoperative cognitive state (MMSE at baseline <25), history of stroke with residuals, increased intracranial pressure
  • Hypersensitivity to the study medication
  • Presumed uncooperativeness or legal incapacity

研究组 & 干预措施

Xenon and propofol

Active Comparator

干预措施: Xenon and propofol (Drug)

propofol

Placebo Comparator

干预措施: propofol (Drug)

结局指标

主要结局

intraoperative haemodynamic stability

时间窗: intra-operative

Haemodynamic stability as assessed by the individual intraoperative noradrenaline consumption

次要结局

  • MACCE (major adverse cardiac and cerebral events)(up to six months postoperative)
  • cerebrovascular accident not included in MACCE(up to six months postoperative)
  • postoperative renal function(up to five days postoperative)
  • requirement for blood(product) transfusion(up to five days postoperative)
  • length of stay(participants will be followed for the duration of hospital stay, an expected average of 10 days.)
  • severity of postoperative critical illness(up to five days postoperative)
  • incidence and duration of postoperative delirium(participants will be followed for the duration of hospital stay, an expectged average of 10 days)
  • incidence of further AE, SAE and SUSAR(participants will be followed for the duration of hospital stay, an expected average of 10 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

prof Dr Steffen Rex

PhD, MD

Universitaire Ziekenhuizen KU Leuven

研究点 (1)

Loading locations...

相似试验